Form 4: Cryo-Cell CIO Reports New Stock Option Grants
Insider Transaction Report
Cryo-Cell International's Chief Information Officer, Oleg Mikulinsky, reported new stock option grants and existing beneficial ownership of common stock and derivative securities.
Summary
- Oleg Mikulinsky, Chief Information Officer of Cryo-Cell International Inc. (CCEL), reported his beneficial ownership and recent stock option grants.
- Mikulinsky directly owns 104,349 shares of Common Stock.
- On January 7, 2026, Mikulinsky was granted two new tranches of stock options: 10,000 options and 20,000 options, both with an exercise price of $3.54 and expiring on January 7, 2031.
- The 10,000 new options vest 1/3 upon issuance, 1/3 on January 7, 2027, and 1/3 on January 7, 2028.
- The 20,000 new options, granted under the Cryo-Cell 2022 Stock Incentive Plan, vest in three equal tranches, each subject to both time-based vesting (first, second, and third anniversaries of grant date) and stock-price performance conditions (average closing price of $6, $8, and $10 respectively over 20 consecutive trading days).
- Mikulinsky also holds several other stock option grants from previous years with various exercise prices and vesting schedules, totaling 63,777 options prior to the new grants.
Sentiment
Score: 5
Explanation: The filing is a standard Form 4 reporting insider beneficial ownership and option grants, which is neutral in sentiment. The grants themselves can be seen as positive for incentive alignment, but the filing does not contain information to suggest a strong positive or negative overall sentiment.
Positives
- New stock option grants align management incentives with shareholder value creation, particularly the performance-based vesting conditions tied to stock price targets of $6, $8, and $10 per share.
- The grants demonstrate continued commitment and retention of a key executive, the Chief Information Officer.
Future Outlook
The vesting schedules for the newly granted stock options, particularly those tied to specific stock price targets ($6, $8, and $10 per share), indicate a forward-looking incentive structure designed to align the Chief Information Officer's interests with future company performance and shareholder value appreciation.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions and does not provide broader industry context or trends. It reflects company-specific compensation and incentive practices for its executives.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Stock Incentive Plan Utilization | The 20,000 stock options granted on January 7, 2026, were issued pursuant to the Cryo-Cell 2022 Stock Incentive Plan and an individual award agreement. These options include performance-based vesting conditions tied to the company's stock achieving average closing prices of $6, $8, and $10 per share over 20 consecutive trading days, in addition to time-based vesting. | 01/07/2026 | Enhances executive incentive alignment with shareholder value creation through performance-based compensation. |
Stakeholder Impact
- Shareholders: Potential future dilution if options are exercised, but also potential benefit from increased executive incentive to drive stock price appreciation.
- Employees: Reflects the company's compensation strategy for key executives, potentially influencing broader employee incentive programs.
Next Steps
- Future vesting of stock options on various dates, contingent on time-based and/or stock-price performance conditions.
- Potential exercise of vested stock options by the reporting person.
Key Dates
| Date | Description |
|---|---|
| 05/21/2018 | Grant date for 8,000 stock options with an exercise price of $7.49, expiring 05/21/2028. |
| 09/04/2019 | Grant date for 4,444 stock options with an exercise price of $7.13, expiring 09/04/2029. |
| 02/27/2020 | Grant date for 1,333 stock options with an exercise price of $6.55, expiring 02/27/2030. |
| 09/23/2021 | Grant date for 10,000 stock options with an exercise price of $8.00, expiring 09/23/2028. These options vest 1/5 per year commencing on this date. |
| 12/28/2021 | Grant date for 20,000 stock options with an exercise price of $11.90, expiring 12/28/2028. These options vest immediately if the company's stock price reaches $25.00 per share during the seven-year option period. |
| 12/22/2023 | Grant date for 10,000 stock options with an exercise price of $5.88, expiring 12/22/2028. These options vest 1/3 upon issuance, 1/3 on December 22, 2024, and 1/3 on December 22, 2025. |
| 12/22/2024 | Vesting date for 1/3 of the 10,000 stock options granted on 12/22/2023. |
| 01/21/2025 | Grant date for 10,000 stock options with an exercise price of $7.35, expiring 01/21/2030. These options vest 1/3 upon issuance, 1/3 on January 22, 2026, and 1/3 on January 22, 2027. |
| 12/22/2025 | Vesting date for 1/3 of the 10,000 stock options granted on 12/22/2023. |
| 01/07/2026 | Transaction date for the acquisition of new stock options by Oleg Mikulinsky. |
| 01/07/2026 | Grant date for 10,000 stock options with an exercise price of $3.54, expiring 01/07/2031. These options vest 1/3 upon issuance, 1/3 on January 7, 2027, and 1/3 on January 7, 2028. |
| 01/07/2026 | Grant date for 20,000 stock options with an exercise price of $3.54, expiring 01/07/2031. These options vest in three equal tranches based on time and stock price performance conditions ($6, $8, $10 average closing price over 20 consecutive trading days). |
| 01/09/2026 | Signature date of the reporting person, Oleg Mikulinsky. |
| 01/22/2026 | Vesting date for 1/3 of the 10,000 stock options granted on 01/21/2025. |
| 01/07/2027 | Vesting date for 1/3 of the 10,000 stock options granted on 01/07/2026. |
| 01/22/2027 | Vesting date for 1/3 of the 10,000 stock options granted on 01/21/2025. |
| 01/07/2028 | Vesting date for 1/3 of the 10,000 stock options granted on 01/07/2026. |
Keywords
CRYO CELL INTERNATIONAL, CCEL, Form 4, insider transaction, stock options, beneficial ownership, Oleg Mikulinsky, Chief Information Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.